What the FDA labels say about taking them together
Fluticasone and nefazodone
Fluticasone's FDA label of December 19, 2024 names nefazodone in its drug interactions (prescription label) section; the nefazodone label PlainMeds reads does not name fluticasone. The fluticasone label: “The use of strong CYP3A4 inhibitors with Fluticasone Propionate DISKUS is not recommended because increased systemic corticosteroid adverse effects may occur.”
Check it at the source: the fluticasone FDA label on DailyMed (effective December 19, 2024, Haleon US Holdings LLC); the nefazodone FDA label on DailyMed (effective July 31, 2025, Teva Pharmaceuticals USA, Inc.).
What does the fluticasone label say about nefazodone?
Fluticasone label, drug interactions (prescription label)The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole) with XHANCE is not recommended because increased systemic corticosteroid adverse effects may occur.
Arnuity Ellipta label (GlaxoSmithKline LLC, October 18, 2023), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ARNUITY ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid adverse effects may occur [see Drug Interactions ( 7.1 ), Clinical Pharmacology ( 12.3 )].
Fluticasone Propionate Diskus label (Sportpharm LLC, July 28, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate DISKUS is not recommended because increased systemic corticosteroid adverse effects may occur [see Drug Interactions ( 7.1 ), Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Arnuity Ellipta, NDA205625), GlaxoSmithKline LLC, effective October 18, 2023 (SPL set 50f193ee-1691-486d-9370-a664df63695c), via openFDA
Source: FDA drug label (Fluticasone Propionate Diskus, NDA020833), Sportpharm LLC, effective July 28, 2026 (SPL set 348cbd8c-edeb-499c-961d-3aeb5cc2cef1), via openFDA
Source: FDA drug label (FLONASE ALLERGY RELIEF), Haleon US Holdings LLC, effective December 19, 2024 (SPL set b6134ba0-b70a-4eac-9a82-cef64b242c1d), via openFDA; the full label on DailyMed
What does the nefazodone label say about fluticasone?
Nefazodone's label (effective July 31, 2025) does not name fluticasone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nefazodone Hydrochloride), Teva Pharmaceuticals USA, Inc., effective July 31, 2025 (SPL set 51ff7db5-aaf9-4c3c-86e6-958ebf16b60f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluticasone | Nefazodone | |
|---|---|---|
| Labeled for | Allergies, Asthma, Eczema (atopic dermatitis) | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.243 per gram 0.05% cream | $1.17 per tablet 100 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once